# A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

> **NCT07478302** · PHASE1 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR-2524 Injection
- **DRUG:** Bevacizumab Injection

## Key facts

- **NCT ID:** NCT07478302
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07478302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07478302, "A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT07478302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*